MX2024005153A - Compuestos y metodos dirigidos a la interleucina-34. - Google Patents
Compuestos y metodos dirigidos a la interleucina-34.Info
- Publication number
- MX2024005153A MX2024005153A MX2024005153A MX2024005153A MX2024005153A MX 2024005153 A MX2024005153 A MX 2024005153A MX 2024005153 A MX2024005153 A MX 2024005153A MX 2024005153 A MX2024005153 A MX 2024005153A MX 2024005153 A MX2024005153 A MX 2024005153A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods targeting
- targeting interleukin
- methods
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 | |
| PCT/US2022/078776 WO2023076995A1 (en) | 2021-10-29 | 2022-10-27 | Compounds and methods targeting interleukin-34 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005153A true MX2024005153A (es) | 2024-05-13 |
Family
ID=84367272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005153A MX2024005153A (es) | 2021-10-29 | 2022-10-27 | Compuestos y metodos dirigidos a la interleucina-34. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11976114B2 (https=) |
| EP (1) | EP4423127A1 (https=) |
| JP (3) | JP7622019B2 (https=) |
| KR (1) | KR20240099349A (https=) |
| CN (1) | CN118475610A (https=) |
| AR (1) | AR127484A1 (https=) |
| AU (1) | AU2022376940A1 (https=) |
| CA (1) | CA3236555A1 (https=) |
| CL (1) | CL2024001303A1 (https=) |
| CO (1) | CO2024005417A2 (https=) |
| CR (1) | CR20240170A (https=) |
| DO (1) | DOP2024000076A (https=) |
| EC (1) | ECSP24032906A (https=) |
| IL (1) | IL312380A (https=) |
| JO (1) | JOP20240103A1 (https=) |
| MX (1) | MX2024005153A (https=) |
| PE (1) | PE20241471A1 (https=) |
| TW (1) | TW202336034A (https=) |
| WO (1) | WO2023076995A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2320942B1 (en) | 2008-07-21 | 2018-03-14 | Probiodrug AG | Diagnostic antibody assay |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| PT3042917T (pt) | 2010-08-12 | 2018-05-02 | Lilly Co Eli | Anticorpos do péptido beta amilóide anti-n3pglu e seus usos |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| MX2017001293A (es) | 2014-07-28 | 2017-05-23 | Nogra Pharma Ltd | Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino. |
| US10703813B2 (en) | 2014-12-19 | 2020-07-07 | Universite De Nantes | Anti IL-34 antibodies |
| PL3988117T3 (pl) * | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| EP3302552A1 (en) | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| EP3496750A2 (en) | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
| TWI705975B (zh) | 2017-04-20 | 2020-10-01 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| WO2019169291A1 (en) | 2018-03-02 | 2019-09-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of il-34 to treat retinal inflammation and neurodegeneration |
| MX2021014473A (es) | 2019-05-31 | 2022-01-06 | Lilly Co Eli | Compuestos y metodos dirigidos a la tau humana. |
| AR121898A1 (es) | 2020-04-30 | 2022-07-20 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
-
2022
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
- 2024-04-29 JO JOJO/P/2024/0103A patent/JOP20240103A1/ar unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022376940A1 (en) | 2024-05-02 |
| US20240309082A1 (en) | 2024-09-19 |
| JP2024091777A (ja) | 2024-07-05 |
| IL312380A (en) | 2024-06-01 |
| PE20241471A1 (es) | 2024-07-17 |
| EP4423127A1 (en) | 2024-09-04 |
| US11976114B2 (en) | 2024-05-07 |
| CR20240170A (es) | 2024-05-24 |
| JP7622019B2 (ja) | 2025-01-27 |
| CA3236555A1 (en) | 2023-05-04 |
| WO2023076995A1 (en) | 2023-05-04 |
| JOP20240103A1 (ar) | 2024-04-29 |
| AR127484A1 (es) | 2024-01-31 |
| ECSP24032906A (es) | 2024-05-31 |
| US20230279094A1 (en) | 2023-09-07 |
| CL2024001303A1 (es) | 2024-08-30 |
| JP2023067832A (ja) | 2023-05-16 |
| KR20240099349A (ko) | 2024-06-28 |
| JP2025063187A (ja) | 2025-04-15 |
| CO2024005417A2 (es) | 2024-05-30 |
| TW202336034A (zh) | 2023-09-16 |
| CN118475610A (zh) | 2024-08-09 |
| DOP2024000076A (es) | 2024-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013617A (es) | Compuestos y metodos dirigidos a interleucina-34. | |
| JOP20230036A1 (ar) | نواهض مستقبل أوريكسين بيروليدين سيكلوهيبتان | |
| BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
| MA54133B1 (fr) | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y | |
| GEP20257842B (en) | High affinity antibodies targeting tau phosphorylated at serine 413 | |
| EA201992688A1 (ru) | Средства, пути применения и способы лечения | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| MY158159A (en) | Novel fused pyrrolocarbazoles | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| PH12021550329A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| MY209459A (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| ZA202110285B (en) | Antibodies and methods of use | |
| MX2024005153A (es) | Compuestos y metodos dirigidos a la interleucina-34. | |
| EA202091340A1 (ru) | Способ получения соединений "лекарственное средство-линкер" | |
| MX2024005144A (es) | Compuestos y metodos dirigidos a la interleucina-34. | |
| MX2024005146A (es) | Compuestos y metodos dirigidos a interleucina-34. | |
| MX2009005351A (es) | Compuestos utiles para tratar trastornos neurodegenerativos. | |
| MY206530A (en) | Methods for treating neurodegenerative disorders | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| MX2024005145A (es) | Compuestos y metodos dirigidos a la interleucina-34. | |
| WO2023004036A3 (en) | Anti-fsh antibodies for neurodegenerative diseases | |
| UA87829C2 (en) | Fused pyrrolocarbazoles | |
| MX2024002599A (es) | Malonamidas herbicidas que contienen un sistema de anillos condensados. | |
| WO2021127621A3 (en) | Compositions and methods for oocyte-specific contraception |